Earnings
Positive
Maze Therapeutics Inc (NASDAQ:MAZE) Reports Narrower Q2 2025 Loss, Extends Cash Runway to 2027
Breaking news from global financial markets
2 months ago
Read More
2 months ago
4,749
2 months ago
1,525
2 months ago
3,474
2 months ago
547
2 months ago
3,085
2 months ago
1,396
2 months ago
980
2 months ago
2,449
2 months ago
2,183
2 months ago
4,678
2 months ago
4,089
2 months ago
2,736
2 months ago
843
2 months ago
1,899
2 months ago
2,278
2 months ago
4,838
Trending Now
1
ROSEN, LEADING INVESTOR COUNSEL, Encourages Telix Pharmaceuticals Ltd. Investors...
14,280
34 minutes ago
2
Kaltura signals transition to AI-driven CX/EX with eSelf acquisition and targets...
21,381
36 minutes ago
3
Apei outlines $640M-$644M full-year revenue target as enrollment momentum drives...
24,241
36 minutes ago
4
Lexington Law Firm Named Best Credit Repair Company of 2026 Reviews by Tidewater...
4,886
42 minutes ago
5
Amid Trillion-Dollar Package Criticism, Elon Musk Reveals He Came To Montreal Wi...
31,893
48 minutes ago